Unique ID issued by UMIN | UMIN000019879 |
---|---|
Receipt number | R000022966 |
Scientific Title | A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC) |
Date of disclosure of the study information | 2015/11/24 |
Last modified on | 2019/12/06 15:54:26 |
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC)
Personalized peptide vaccination with metformin for CRPC
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC)
Personalized peptide vaccination with metformin for CRPC
Japan |
Castration-resistant prostate cancer
Urology |
Malignancy
NO
The aim of study is to investigate the immunity-enhancing effects, safety , clinical efficacy of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer patients.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
Assessment of immune responses by measurement of cytotoxic T lymphocytes (CTL)and anti-peptide IgG) before and after peptide vaccination with metformin.
1.Evaluation of long-term prognosis (progression free survival and overall survival).
2.Adverse effects of peptide vaccination / The safety of the protocol is evaluated based on the NCI-CTC.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine | Vaccine |
1st cycle:
(Personalized peptide vaccination alone)
4 peptide vaccines are selected from 31 peptide candidates restricted by HLA-class I, to which peptide-specific IgGs are detected before vaccination, and administer peptides (maximum 4) that showed the highest reactivity. Emulate these peptides individually and subcutaneously inject them separately (3.0 mg/1.5-3.0 ml/peptide) every 1 week interval:
total 8 times, every weeks.
After 1st cycle:
(Personalized peptide vaccination in combination with metformin)
Start oral use of metformin (500mg/day, 2X, every days) with personalized peptide vaccination.
If the patients want to continue the vaccination after completion of the second cycle of 8 vaccinations, the peptide vaccination with metformin will be allowed to continue (every 3-4 weeks) until unacceptable toxicity or withdrawal of consent.
20 | years-old | <= |
Not applicable |
Male
The subjects must satisfy the following conditions.
1) Patients must be diagnosed as prostate cancer pathologically at the initial treatment. The patients must be suffering from castration-resistant prostate cancer after standard treatment.
2) Patients have not been diagnosed as diabetes, and patients must satisfy the followings:
HbA1c < and = 6.5%
Patients do not receive medical therapy
using the diabetes medicine (including an oral hypoglycemic drug, the insulin
therapy).
3) Patients must be at a score level
of 0-1 of performance status (PS) (ECOG).
4) Patients must be positive for HLA-A2, HLA-A24 or HLA-A3 super type.
5) Patients must have IgG reactive to at least two of peptide the candidate peptides restricted to the patient's HLA types.
6) Patients must satisfy the followings:
WBC >and= 2,500/mm3
Lymphocyte >and=1,000/mm3
Hb >and= 8.0g/dl
Platelet >and= 80,000/mm3
Serum Creatinine <and= 1.5x upper limit of normal
Total Bilirubin <and=2x upper limit of normal
AST, ALT <and = 2x upper limit of normal
7) Patients must be more 20 year-old.
8) Patients must be expected to survive more than 3 months.
9) Written informed consent must be obtained from patients.
The following patients must be excluded:
1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation).
2)Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment.
3) Patients with the past history of severe allergic reactions.
4) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination.
5) Patients who are judged inappropriate for entry to this clinical trial by doctors.
35
1st name | |
Middle name | |
Last name | Masanori Noguchi |
Kurume University School of Medicine
Research Center for Innovative Cancer Therapy, Division of Clinical Research
Asahi-machi 67, Kurume, Fukuoka 830-0011, Japan
0942-31-7989
noguchi@med.kurume-u.ac.jp
1st name | |
Middle name | |
Last name | Akira Yamada |
Kurume University School of Medicine
Research Center for Innovative Cancer Therapy, Division of Cancer Vaccine
Asahi-machi 67, Kurume, Fukuoka 830-0011, Japan
0942-31-7572
akiymd@med.kurume-u.ac.jp
Cancer Vaccine Center, Kurume University School of medicine
None
Self funding
Kurume University
NO
久留米大学病院医療センター(福岡)Kurume University Medical Center (Fukuoka)
2015 | Year | 11 | Month | 24 | Day |
Unpublished
Completed
2015 | Year | 11 | Month | 17 | Day |
2015 | Year | 11 | Month | 17 | Day |
2015 | Year | 11 | Month | 24 | Day |
2020 | Year | 11 | Month | 30 | Day |
2015 | Year | 11 | Month | 20 | Day |
2019 | Year | 12 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022966
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |